Dry (Atrophic) Macular Degeneration Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Dry (Atrophic) Macular Degeneration Clinical Trial Report Overview
A total of 145 dry (atrophic) macular degeneration clinical trials were conducted as of March 2024. The dry (atrophic) macular degeneration clinical trial report provides a comprehensive understanding of the dry (atrophic) macular degeneration clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials.
Key Regions | · North America
· Europe · Asia-Pacific · Middle East and Africa · South and Central America |
Key Countries | · United States
· Australia · United Kingdom · Germany · Italy |
Key Sponsor Types | · Company
· Institution · Government |
Leading Sponsors | · Astellas Pharma Inc
· F. Hoffmann-La Roche Ltd · Biophytis SA · Johnson & Johnson · Kubota Pharmaceutical Holding |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Dry (Atrophic) Macular Degeneration Clinical Trials Segmentation by Regions and Countries
As of March2024, North America led the dry (atrophic) macular degeneration clinical trials landscape with more than 50% of the clinical trials conducted there
The key regions considered for dry (atrophic) macular degeneration clinical trials analysis are North America, Europe, Asia-Pacific, the Middle East and Africa, and South and Central America.
In the country wise analysis, The US had the highest number of dry (atrophic) macular degeneration clinical trials, as of March 2024. Hungary had the highest average patient enrollment in dry (atrophic) macular degeneration clinical trials during the same time.
G7 countries: Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada and Japan) countries, The United States have the highest proportion of dry (atrophic) macular degeneration to ophthalmology clinical trials as of March 2024.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey and Indonesia) countries, Turkey have the highest proportion of dry (atrophic) macular degeneration to ophthalmology clinical trials as of March 2024.
Dry (Atrophic) Macular Degeneration Clinical Trials Analysis by Regions, 2024 (%)
Buy the Full Report for More Regional Insights into the Dry (Atrophic) Macular Degeneration Clinical Trials
Dry (Atrophic) Macular Degeneration Clinical Trials Segmentation by Sponsor Types
The key sponsor types for dry (atrophic) macular degeneration clinical trials are company, institution, and the government. As of March 2024, more than 23% of dry (atrophic) macular degeneration clinical trials conducted were sponsored by company sponsor type, followed by institution.
Dry (Atrophic) Macular Degeneration Clinical Trials Analysis by Sponsor Types, 2024 (%)
Buy the Full Report for More Sponsor Type Insights into the Dry (Atrophic) Macular Degeneration Clinical Trials
Dry (Atrophic) Macular Degeneration Clinical Trials - Competitive Landscape
In 2024, Astellas Pharma Inc conducted the highest number of dry (atrophic) macular degeneration clinical trials
A few of the leading sponsors for dry (atrophic) macular degeneration clinical trials are:
- Astellas Pharma Inc
- Hoffmann-La Roche Ltd
- Biophytis SA
- Johnson & Johnson
- Kubota Pharmaceutical Holding
Dry (Atrophic) Macular Degeneration Clinical Trials Analysis by Sponsors, 2024 (%)
Buy the Full Report to Know More about the Leading Sponsors of Dry (Atrophic) Macular Degeneration Clinical Trials
Segments Covered in the Report
Dry (Atrophic) Macular Degeneration Clinical Trials Regional Outlook (2024)
- North America
- Europe
- Asia-Pacific
- Middle East and Africa
- South and Central America
Dry (Atrophic) Macular Degeneration Clinical Trials Country Outlook (2024)
- United States
- Australia
- United Kingdom
- Germany
- Italy
- Spain
- Canada
- France
- Hungary
- Austria
Dry (Atrophic) Macular Degeneration Clinical Trials Sponsor Type Outlook (2024)
- Company
- Institution
- Government
Scope
- The report provides a snapshot of the global clinical trials landscape.
- The report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status.
- The report reviews the top companies involved and enlists all trials (trial title, phase, and status) of the company.
- The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with a reason for accomplishment.
- The report provides enrollment trends for the past five years.
- The report provides the latest news for the past three months.
Reasons to Buy
- Formulate key business strategies with regard to investment.
- Identify prominent locations for conducting clinical trials which saves time and cost.
- Get top level analysis of the Global Clinical Trials Market which helps in identifying key business opportunities.
- Understand trial count and enrollment trends by country in the global therapeutics market.
- Interpret the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.
- Understand clinical trial assessment of the indication on a global, regional, and country level.
F. Hoffmann-La Roche Ltd
Biophytis SA
Johnson & Johnson
Kubota Pharmaceutical Holding
Lin Bioscience Inc
Novartis AG
Robert W. Snyder MD, PhD, PC
Snyder Biomedical Corp
Vision Medicines Inc (Inactive)
Table of Contents
Table
Figures
Frequently asked questions
-
Which region accounted for the highest number of dry (atrophic) macular degeneration clinical trials in March 2024?
North America accounted for the highest number of dry (atrophic) macular degeneration clinical trials as of March 2024.
-
Which country conducted the highest number of dry (atrophic) macular degeneration clinical trials in March 2024?
The US conducted the highest number of dry (atrophic) macular degeneration clinical trials as of March 2024.
-
Which sponsor type was the most prominent in the dry (atrophic) macular degeneration clinical trials in March 2024?
As of March 2024, most of the dry (atrophic) macular degeneration clinical trials conducted were sponsored by company sponsor type.
-
Which are the leading sponsors of dry (atrophic) macular degeneration clinical trials?
A few of the leading sponsors of dry (atrophic) macular degeneration clinical trials are Astellas Pharma Inc, F. Hoffmann-La Roche Ltd, Biophytis SA, Johnson & Johnson and Kubota Pharmaceutical Holding among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.